Skip to main content

Table 3 Bivariate and multivariable analysis of CRPA cultures evaluating association between patient/facility characteristics and 90-day mortality

From: Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Characteristics

[n = 8204]

Death 90 days after culture date

(%) [N = 2012]

No death 90 days after culture date

(%) [N = 6192]

Unadjusted odds ratio

(95% CI)

Adjusted odds ratio

(95% CI)

Demographic and clinical characteristics

    

 Male

1983 (98.6)

6019 (97.2)

1.97 (1.32–2.92)

Age category

    

  18–49

36 (1.8)

354 (5.7)

Reference

Reference

  50–64

378 (18.8)

1516 (24.5)

2.45 (1.71–3.52)

1.83 (1.24–2.69)

  65 + 

1598 (79.4)

4322 (69.8)

3.63 (2.57–5.14)

2.96 (2.04–4.29)

 Race

    

  White

1514 (75.3)

4908 (79.3)

Reference

  African American

469 (23.3)

1181 (19.1)

1.29 (1.15–1.45)

  Other*

29 (1.4)

103 (1.7)

0.91 (0.60–1.38)

 Ethnicity

    

  Non-Latine

1799 (89.4)

5737 (92.7)

Reference

  Latine

213 (10.6)

455 (7.3)

1.49 (1.26–1.77)

 Region

    

  South

861 (42.8)

2533 (40.9)

Reference

Reference

  Midwest

370 (18.4)

1334 (21.5)

0.82 (0.71–0.94)

0.77 (0.66–0.90)

  West

391 (19.4)

1377 (22.2)

0.84 (0.73–0.96)

0.85 (0.73–0.99)

  Northeast

242 (12.0)

707 (11.4)

1.01 (0.95–1.19)

0.83 (0.69–1.00)

  U.S. Territory

148 (7.4)

241 (3.9)

1.81 (1.45–2.25)

1.23 (0.96–1.58)

 Rurality

    

  Urban

1892 (94.0)

5733 (92.6)

Reference

  Rural

120 (6.0)

459 (7.4)

0.79 (0.64–0.98)

 Facility complexity

    

  High

1908 (94.8)

5578 (90.1)

Reference

  Low

104 (5.2)

614 (9.9)

0.50 (0.40–0.61)

 Care setting

    

  Outpatient

398 (19.8)

3117 (50.3)

Reference

Reference

  Long-term care

205 (10.2)

838 (13.5)

1.92 (01.59–2.31)

1.08 (0.86–1.36)

  Inpatient

1409 (70.0)

2237 (36.1)

4.93 (4.36–5.58)

2.95 (2.58–3.38)

 Specimen type

    

  Urine

758 (37.7)

3565 (57.6)

Reference

Reference

  Respiratory

823 (40.9)

936 (15.1)

4.12 (3.66–4.56)

2.58 (2.25–2.96)

  Blood

91 (4.5)

93 (1.5)

4.60 (3.41–6.21)

2.82 (2.04–3.90)

  Other

340 (16.9)

1598 (25.8)

1.00 (0.87–1.15)

0.84 (0.72–0.98)

Co-morbidities

    

 Mean Charlson Score (SD)

6 (3.1)

4 (2.9)

 < 0.0001§

1.13 (1.11–1.15)

 SCI/D

    

  No

1813 (90.1)

5083 (82.1)

Reference

Reference

  Yes

199 (9.9)

1109 (17.9)

0.50 (0.43–0.59)

0.64 (0.53–0.77)

Antibiotic exposure in previous 90 days

    

 Any antibiotics

    

  No

1409 (70.0)

3445 (55.6)

Reference

Reference

  Yes

603 (30.0)

2747 (44.40

0.54 (0.48–0.60)

0.58 (0.52–0.66)

 Fluoroquinolones

    

  No

1765 (87.7)

5098 (82.3)

Reference

  Yes

247 (12.3)

1094 (17.7)

0.65 (0.56–0.76)

 3rd and 4th generation cephalosporins

    

  No

1960 (97.4)

5971 (96.4)

Reference

  Yes

52 (2.6)

221 (3.6)

0.72 (0.53–0.97)

 Carbapenems

    

  No

1999 (99.4)

6163 (99.5)

Reference

  Yes

13 (0.6)

29 (0.5)

1.38 (0.72–2.66)

 Length of stay 1 year prior to culture

    

  Mean, median (SD)

73, 38 (92.1)

42, 10 (75.6)

 < 0.0001§

1.00 (1.00–1.00)

  1. Significant associations are shown in bold (p < 0.05)
  2. *Other includes, Asian, Native American and Pacific Islander
  3. Other specimen types include wounds, skin/soft tissue, body fluid, bone/joint, rectal cultures
  4. Respiratory specimen types include bronchial alveolar, tracheal aspirate, induced sputum, etc.
  5. §t-test p-value